ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to DupilumabGlobeNewsWire • Tuesday
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis PatientsGlobeNewsWire • 04/22/24
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/12/24
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?Zacks Investment Research • 04/09/24
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and DisordersGlobeNewsWire • 03/27/24
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for FarudodstatGlobeNewsWire • 02/29/24
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewsWire • 01/08/24
ASLAN Pharmaceuticals Announces Participation in January Investor ConferencesGlobeNewsWire • 01/02/24
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat ProgramsGlobeNewsWire • 12/12/23
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development SummitGlobeNewsWire • 11/03/23
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 10/27/23
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic DermatitisGlobeNewsWire • 10/18/23
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology CongressGlobeNewsWire • 10/13/23
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology CongressGlobeNewsWire • 09/22/23
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/07/23
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/23
Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatmentMarket Watch • 07/06/23
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic DermatitisGlobeNewsWire • 07/06/23
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic DermatitisGlobeNewsWire • 07/05/23
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab's Unique Mechanism of Action in the Treatment of Atopic DermatitisGlobeNewsWire • 06/23/23
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in JapanGlobeNewsWire • 06/22/23